5 results
To evaluate the effect of benralizumab 100 mg on COPD exacerbations in patients with moderate to very severe COPD.
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatory eosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-head comparison of the presence…
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatoryeosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-headcomparison of the presence of…
Primary objectives:•To determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RPTD) of ABBV-155 administered as monotherapy (Part 1a)•To determine MTD and RPTD of ABBV-155 administered in combination with paclitaxel or docetaxel (…
The objective of this Phase 3 study is to investigate the safety and efficacy of benralizumab as a treatment for patients with eosinophilic esophagitis.